MORPHOLOGICAL CHANGES IN THE LIVER OF CHILDREN WITH CYSTIC FIBROSIS
Abstract
Background. Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, characterized by damage to vital organs, a severe course and an unfavorable outcome. Liver cirrhosis is a relatively rare manifestation of cystic fibrosis. Objective. To study the causes of death, hepatic morphological changes in CF according to autopsy data and to present a description of a case of CF with rapidly progressing liver cirrhosis in a 6-year-old child. Material and methods. An analysis of clinical, laboratory and instrumental studies of CF and the results of hepatic morphological changes was carried out according to the data of 10 autopsies performed at the State Healthcare Institution "GRCPB". Results. Among the 10 patients died from a mixed form of CF, there were 5 patients aged 1-3 months, 2 patients aged 1.5 years, 1 patient aged 4.5 years, 1 patient aged 6 years and 1 patient was 19 years old. Infant patients had predominant intestinal damage with the development of intestinal obstruction and peritonitis, older age groups had lung damage with the development of chronic pulmonary heart disease, chronic pulmonary heart failure, and to a lesser extent - pathology of the pancreas and gastrointestinal tract. In one 6-year-old patient, CF was complicated by diabetes mellitus as well as liver cirrhosis with portal hypertension. All patients had severe protein-energy deficiency, psychosomatic and psychopathological symptoms. The results of pathohistological examination of the liver of infant patients showed dilation of the interlobular bile ducts with cholestasis and periductal fibrosis. The severity of these liver changes increased gradually alongside with patients’ age, including the progression of fatty degeneration. In a number of cases, diffuse fibrosis was recorded, resulting in liver cirrhosis with portal hypertension. At autopsy, the extrahepatic bile ducts and gallbladder were dilated and filled with bile of a viscous consistency. Conclusions. The nature of hepatic morphological changes in CF depends on the age of the patients and on the influence of exogenous factors. Only timely diagnosis and early complex therapy for CF will reduce the progression of irreversible processes in various organs and prolong the life of patients.
References
Avdeev SN, Avetisjan LR, Amelina EL, Asherova IK. Mukoviscidoz. 2nd ed. Moskva: Medpraktika-M; 2021. 679 p. (Russian).
Kondratjeva EI, Kashirskaja NJu, Kapranov NI, editors. Nacionalnyj konsensus Mukoviscidoz: opredelenije, diagnosticheskije kriterii, terapija [Internet]. Moskva: OOO "Kompanija BORGES"; 2016. 205 p. Available from: https://mukoviscidoz.org/doc/konsensus/CF_consensus_2017.pdf (Russian).
Kashirskaya NYu, Kapranov NI, Kusova ZA, Asherova IK, Voronkova AYu. Porazhenije gepatobiliarnoj sistemy pri mukoviscidoze. Pediatriya. Zhurnal im. G.N. Speranskogo. 2012;91(4):106-115. edn: PAMJSZ. (Russian).
Petrova NV. Molekuljarno-geneticheskije i kliniko-genotipicheskije osobennosti mukoviscidoza v rossijskih populjacijah [dissertation]. Moskva (Russia); 2009. 305 p. edn: QEIAFB. (Russian).
Kashirskoj NJu, Kondratevoj EI, Krasovskogo SA, Starinovoj MA, Voronkovoj AJu, Amelinoj EL, Asherovoj IK. Registr bolnyh mukoviscidozom v Rossijskoj Federacii. 2019 god. Moskva: Medpraktika-M; 2021, 68 p. (Russian).
Ponomareva TA. Regionalnyje osobennosti mukoviscidoza i elementnogo statusa u detej Stavropolskogo kraja [master's thesis]. Stavropol (Russia); 2019. 170 p. edn: BAIJCO. (Russian).
Voitovich TN, Bobrovnichy VI, Chisty AG. Cystic fibrosis in children. modern features of the clinic, diagnosis and treatment. Medical journal. 2020;(2(72)):130-134. edn: GSGWAF. (Russian).
Volkova MP, Vezhel OV, Zaryhta VV, Hotjan KI. Mukoviscidoz u detej Grodnenskoj oblasti. In: Paramonova NS, editor. Aktualnyje voprosy pediatrii. Sbornik materialov mezhregionalnoj nauchno-prakticheskoj konferencii s mezhdunarodnym uchastiem; 2018 April 19-20; Grodno. Grodno: GrSMU; 2018. p. 39-42. edn: ZCLNDN. (Russian).
Pukhalsky AL, Shmarina GV, Kapranov NI. Inflammatory markers in cystic fibrosis patients. Pulmonologiya. 2002;(5):39-42. (Russian).
Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-9. https://doi.org/10.1164/rccm.201207-1160oe.
Kumar V, Abbas AK, Aster DS. Patologicheskaja anatomija po Robbinsu. Moskva: "GJeOTAR-Media"; 2022. 1136 p. https://doi.org/10.33029/9704-6467-0-KRB-2022-1-1036. https://elibrary.ru/vphgkq. (Russian).
Hodson M, Duncan G, Bush A. Cystic Fibrosis, Liver and Biliary Disease in Cystic Fibrosis. 3rd ed. London: Edward Arnold (Publishers) Ltd; 2007. 477 p.
Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004;41(6):920-5. https://doi.org/10.1016/j.jhep.2004.08.006.
Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, et al. Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009;302(10):1076-83. https://doi.org/10.1001/jama.2009.1295.
Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10 Suppl 2:S29-36. https://doi.org/10.1016/S1569-1993(11)60006-4.
